Neoadjuvant Selective COX-2 Inhibition Downregulates Important Oncogenic Pathways in Patients With Esophageal Adenocarcinoma

European Journal of Gastroenterology and Hepatology - United States
doi 10.1097/00042737-200601000-00092
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Ovid Technologies (Wolters Kluwer Health)

Related search

Vitamin D Receptor Expression and Neoadjuvant Therapy in Esophageal Adenocarcinoma

Experimental and Molecular Pathology
Forensic MedicinePathologyClinical BiochemistryMolecular Biology
2012English

Progression of Pancreatic Adenocarcinoma Is Significantly Impeded With a Combination of Vaccine and COX-2 Inhibition

Journal of Immunology
AllergyImmunology
2008English

Prognostic Significance of Cyclooxygenase-2 (COX-2) Expression in Patients With Surgically Resectable Adenocarcinoma of the Oesophagus

BMC Cancer
Cancer ResearchOncologyGenetics
2006English

Esophageal Adenocarcinoma in a First-Degree Relative Increases Risk for Esophageal Adenocarcinoma in Patients With Barrett’s Esophagus

United European Gastroenterology Journal
OncologyGastroenterology
2018English

Long-Term Remission Following Treatment With Radiotherapy and Selective COX-2 Inhibitor in Two Dogs With Mandibular Salivary Gland Adenocarcinoma

Journal of the Japan Veterinary Medical Association
2010English

Gastrointestinal Tolerability of the Selective Cyclooxygenase-2 (COX-2) Inhibitor Rofecoxib Compared With Nonselective COX-1 and COX-2 Inhibitors in Osteoarthritis

Archives of Internal Medicine
2000English

Substrate-Selective COX-2 Inhibition as a Novel Strategy for Therapeutic Endocannabinoid Augmentation

Trends in Pharmacological Sciences
ToxicologyPharmacology
2014English

Viscum Album-Mediated COX-2 Inhibition Implicates Destabilization of COX-2 mRNA

PLoS ONE
Multidisciplinary
2015English

Salvage Endoscopic Resection in Patients With Esophageal Adenocarcinoma After Chemoradiotherapy

Endoscopy International Open
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy